©2018 by EpiCombi Therapeutics. Proudly created with Wix.com

EPICOMBI THERAPEUTICS

RATIONAL DRUG COMBINATION DESIGN 

EpiCombi has developed a platform technology that enables the identification of optimised epigenetic-driven drug combinations for cancer and other intractable disease conditions

 

Machine Learning to resolve complexity in disease biology to create more effective therapeutic agents

Our Story

The biological drivers of cancer and other intractable disease conditions are the result of complex network interactions; conventional efforts to reduce these down to single pharmacological targets have proven therapeutically inadequate. Hence, these diseases remains, for the most part, intractable exhibiting significant morbidity and/or mortality. To disrupt such complexity and restore normal function in order to modify the course of these diseases, requires hitting these complex networks from multiple angles. To achieve this one needs to:

  • collect disease-relevant biological data

  • analyse data patterns  that identify mechanistic drivers and,

  • link these mechanisms to drug agents

all in order to generate drug therapeutic concepts that can lead to more effective treatments. In cancer  this means identifying drugs that simultaneously activate and/or block multiple networks to create a condition of synthetic lethality from which the cancer cell cannot recover. In the main, this requires: 1) rendering these dysregulated cells more vulnerable to detection by the immune system and, 2) inhibiting proliferative mechanisms that result infettered growth and metastasis.

EpiCombi, an Oxford University spinout, has developed a Machine Learning and screening-driven platform that enable the filtering of large amounts of data, can efficiently detect meaningful patterns in this data, all of which leads to generate combination candidate for further screening using cancer indication-derived biomarkers.

 

Our Technology

Mining biological complexity to generate meaningful drug candidates

EpiCombi's platform enables the mining of gene networks in complex disease biology through the analysis of drug-induced gene-signatures. Using Machine learning and pattern recognition in large datasets, EpiCombi's platform identifies drug-linked mechanisms that yield drug combination prototypes that can be further validated using biomarker-driven high-content screening and lead to the development of more effective proprietary drugs for intractable diseases. While the company's initial targets are in cancer, this technology is equally applicable to the discovery and development of effective therapeutic agents for the treatment of other intractable disease conditions. Drug combinations so discovered are then validated in clinically relevant high content in vitro and in vivo models leading to the initiation of proprietary drug development programs.

 

Steven Zimmer

Founder and CEO

Steven is the founder and co-founder of a number of biotech start-ups including Protein Sciences, recently acquired by Sanofi Pasteur. He has a BSc(Hon) in Biochemistry and and MSc in Molecular Biology. The bulk of his career was spent on Wall Street and in the City of London with firms such as F.Eberstadt & Co, Robert Fleming, DLJ and CSFB where he was an analyst, investment banker and portfolio manager. More recently he has worked with e-Therapeutics and Selventa in Business and strategic development roles

Professor Avi Ma'ayan

Acting CTO and Scientific advisor

Avi is the Director of the Center for Bioinformatics and Professor of Pharmacological Sciences at the Mount Sinai Icahn School of Medicine. He is also Principal Investigator of the NIH-funded BD2K-LINCS Data Coordination and Integration Center and Mount Sinai Knowledge Management Center for Illuminating the Druggable Genome

Andrew Wood

CFO

Andrew has a first class BA from Oxford in Biochemistry and is a Chartered
Accountant with extensive finance and commercial experience in startup, early stage and established biotech
businesses. For 16 years, he was CFO and Company Secretary of Oxford Biomedica plc.

Professor Chas Bountra

Scientific Advisor

Prof. Bountra is the CSO of the Structural Genomics Consortium and Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor to many academic, biotech and pharma drug discovery programmes. Chas was head of Biology at GSK and is a scientific advisor to Carrick Pharmaceuticals.

Professor Paul Workman

Scientific Advisor

Paul is the Chief Executive Officer and President of the Institute for Cancer Research in London. Previously he was the Head of Cancer Bioscience Resaerch at Astra Zeneca where he developed a partnership with Sugen. He was the scientific co-founder of Chroma Therapeutics and Piramed (acquired by Roche).

Professor Stephen Haggarty

Scientific Advisor

Steve is an Associate Professor of Neurology at Harvard Medical School and Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital. He is also a Senior Associate member of the Broad Institute of Harvard and MIT.

Professor Paul Brennan

Advisor and Consultant

Paul is an Associate Professor of Medicinal Chemistry in the SGC, Nuffield Department of Medicine at Oxford University. He is a principal investigator and Group lead In both the SGC and the TDI at Oxford with a focus on designing chemical probes for various disease conditions. Previously he was Design Lead at Pfizer and a medicinal chemist at Amgen.

Prof. Katherine Chiappinelli

Advisor and Consultant

Kate is an Assistant Professor of Microbiology, Immunology and Tropical Medicine at the George Washington University School of Medicine. Her focus is on epigenetic regulation of immune signalling in cancer. {reviously, she was a post doctoral fellow in Prof. Stephen Baylin's group at Johns Hopkins.

Dr Matthew Fuchter

Advisor and Consultant

Matt is a Reader in Chemistry at Imperial College London where he is also the Director of Post-Graduate studies in the Department of Chemistry and co-Director of the MRes in Drug Discovery

 

Get in Touch